510(k) · Cleared
ClearedRelivion
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Neurolief, Ltd. · PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine
Cleared on Feb 16, 2021 as substantially equivalent to K171446 (Cefaly Technology, 2017) after an 89-day review. Its family tree reaches back 3 generations to 2014. 1 later device descends from it.
- Decided
- Feb 16, 2021
- Review
- 89 days
- Class
- Class II
- Product code
- PCC
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 3 generations to DEN120019 (2014). 1 later device descends from it, 1 citing it directly.
- Root · 3 generations backDEN120019 CefalyStx-Med Sprl · 2014
- 2 generations backK160237 CefalyCefaly Technology · 2016
- 1 generation backK171446 Cefaly AcuteCefaly Technology · 2017
- This deviceK203419 RelivionNeurolief, Ltd. · 2021
- Descendant · cites it directly · 0 of its ownK212106 RelivionNeurolief, Ltd. · 2021
Most influential descendants
Showing 1 of 1 · See all- K212106RelivionNeurolief, Ltd. · 2021 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −3 | DEN120019 | Cefaly | Stx-Med Sprl | 2014 | — |
| −2 | K160237 | Cefaly | Cefaly Technology | 2016 | — |
| −1 | K171446 | Cefaly Acute | Cefaly Technology | 2017 | — |
| 0 (this device) | K203419 | Relivion | Neurolief, Ltd. | 2021 | — |
| +1 | K212106 | Relivion | Neurolief, Ltd. | 2021 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2021 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in PCC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new PCC device
- #1 K201895 Cefaly Dualscore 16.0 · 4 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K171446 | Cefaly AcuteSummary page 4…treat headache Product Code: PCC Classification: Class II Classification Panel: Neurology Predicate Device: CEFALY Technology's Cefaly® Acute (K171446) Intended Use/Indication for Use: Traditional 510(k) Submission – Relivion® – Neurolief Ltd. === Page 5… | 2017 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K212106 | Relivion | 2021 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 7 years and passes through 3 companies; a new generation was cleared every 2.0 years on median.
- None of the 3 ancestors has a recall.
- Of its descendants, K212106 (Neurolief, Ltd., 2021) has gone furthest, with 0 descendants of its own.
- 1 other device also cites its predicate K171446.
How does its category compare?
All PCC devicesPCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.
FDA decisions per year · PCC
5in 2024
2026 to Oct 25, outlined.
Median 510(k) review, days · PCC
211in 2024
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · PCC
No recall names PCC since 2007.
Adverse event reports per year · PCC
2in 2025
MAUDE reports naming product code PCC, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 1 | — | 0 | 2 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 1 | — | 0 | 2 |
| 2017 | 2 | — | 0 | 2 |
| 2018 | 1 | — | 0 | 0 |
| 2019 | 1 | — | 0 | 2 |
| 2020 | 1 | — | 0 | 1 |
| 2021 | 4 | 88 | 0 | 7 |
| 2022 | 1 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 2 |
| 2024 | 5 | 211 | 0 | 6 |
| 2025 | 0 | — | 0 | 2 |
| 2026 | 1 | — | 0 | — |
What is it indicated for?
The Relivion® transcutaneous electrical nerve stimulator is indicated for the acute treatment of migraine
with or without aura in patients 18 years of age or older. It is a prescription device to be self-used at
home.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K203419 · printed Nov 6, 2026
Cite this page
510(k) Report. “K203419: Relivion.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K203419
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026